CT-RCC human endogenous retrovirus group E-derived (HERV-E-derived) CTL epitope peptides, peptide library and application of CTL epitope peptides

• Main Authors: YUE YING, LIANG JIULIN, ZHAO YUXIAO, HAN HUI, DING YUE, ZHANG TENG, XIAO JIANRU, TAN YUANYUAN, GUO WEIQING
• Format: Patent
• Language: Chinese; English
• Published: 05.05.2020
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention relates to CT-RCC human endogenous retrovirus group E-derived (HERV-E-derived) CTL epitope peptides, a peptide library and application of the CTL epitope peptides. The CT-RCC HERV-E-derived CTL epitope peptides of SEQ ID No.1-16 are included; and the peptide library comprises more than two peptides of amino acid sequences. The CT-RCC HERV-E-derived CTL epitope peptides can be appliedto preparing renal clear cell carcinoma vaccines, and have huge potential value in the aspect of immunological therapy of renal clear cell carcinoma. 本发明涉及CT-RCC HERV-E来源的CTL表位肽、肽库及其应用，包括SEQ ID No.1至16氨基序列的CT-RCC HERV-E来源的CTL表位肽，肽库，包含两种以上上述氨基序列的肽，上述CT-RCC HERV-E来源的CTL表位肽可以应用于制备肾透明细胞癌疫苗，在肾透明细胞癌的免疫治疗方面有巨大的潜在价值。